Ending the Silent Epidemic of
Avoidable Amputations.
Every 20 seconds, a limb is lost to diabetes somewhere in the world. ZegeneX was founded on the conviction that geography, income, and cold-chain logistics should never dictate whether a patient walks again.
Over 85% of lower-limb amputations worldwide begin with a seemingly minor foot ulcer that stalled in the natural biological healing cascade.
Major diabetic limb loss carries a 5-year mortality rate higher than colon cancer, breast cancer, or prostate cancer.
Due to prohibitive costs ($5k–$15k) and complex cold-chain storage, 94% of US DFU patients never receive advanced cellular or tissue therapy.
Bridging the Deep Healthcare Access Divide
In premier urban medical centers across high-income countries, patients with non-healing diabetic foot ulcers occasionally access specialized multi-disciplinary wound centers equipped with hyperbaric oxygen chambers, cryopreserved living skin substitutes, and negative-pressure wound therapy.
Yet for the vast majority of the 589 million adults living with diabetes globally today (projected to reach 853 million by 2050 per the IDF Diabetes Atlas 11th Edition), such infrastructure simply does not exist. In rural communities, community health centers, veterans' clinics, and developing nations, biologic therapies spoil in transit because local facilities lack continuous sub-zero refrigeration.
Democratizing Advanced Regenerative Medicine
By encapsulating biologic-level regenerative potency into an ambient-stable (25°C, 24+ months) synthetic small-molecule topical, Zegen-X5 can be stocked in neighborhood pharmacies, mailed directly to patient homes, and administered simply by nurses, caregivers, or patients themselves.